Saltar al contenido
Merck

Documentos clave

Ver Toda la documentación

567430

Sodium Butyrate

≥98% (titration), apoptosis inducer, solid

Sinónimos:

Sodium Butyrate, Butyric Acid, Na, NaB, HDAC Inhibitor V

Iniciar sesión para ver los precios por organización y contrato.

Seleccione un Tamaño

Cambiar Vistas

Acerca de este artículo

Fórmula empírica (notación de Hill):
C4H7NaO2
Número CAS:
156-54-7
Peso molecular:
110.09
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
MFCD00002816
Assay:
≥98% (titration)
Form:
solid
Quality level:
200
Storage condition:
OK to freeze, desiccated (hygroscopic)
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarle

Nombre del producto

Sodium Butyrate, A short chain fatty acid that has been shown to induce apoptosis in colon carcinoma cell lines by a p53-independent pathway.

Quality Level

200

description

RTECS - ET6400000

assay

≥98% (titration)

form

solid

manufacturer/tradename

Calbiochem®

storage condition

OK to freeze, desiccated (hygroscopic)

color

white

solubility

water: 2 mg/mL

shipped in

ambient

storage temp.

−20°C

SMILES string

[Na+].[O-]C(=O)CCC

InChI

1S/C4H8O2.Na/c1-2-3-4(5)6;/h2-3H2,1H3,(H,5,6);/q;+1/p-1

InChI key

MFBOGIVSZKQAPD-UHFFFAOYSA-M

General description

A short chain fatty acid that has been shown to induce apoptosis in colon carcinoma cell lines by a p53-independent pathway. Inhibits c-myc splicing and interferes with signal transduction processes, including the release of Ca2+ from intracellular stores. Reduces histamine-induced calcium mobilization in C6 glioma cells. Down-regulates the activity of the serine/threonine protein kinase casein kinase II in HT29 cells.

Biochem/physiol Actions

Cell permeable: no
Primary Target
Induce apoptosis
Product does not compete with ATP.
Reversible: no

Preparation Note

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Other Notes

Ou, H.C., et al. 1997. Neuroreport 8, 1375.
Russo, G.L., et al. 1997. Biochem. Biophys. Res. Commun. 233, 673.
Krupitza, G., et al. 1995. Carcinogenesis16, 1199.
Calabresse, C., et al. 1993. Biochem. Biophys. Res. Commun.195, 31.
Hague, A., et al. 1993. Int. J. Cancer55, 498.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Toxicity: Irritant (B)

Still not finding the right product?

Explore all of our products under

pictograms

Exclamation mark
GHS07

signalword

Warning

Hazard Classifications

Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2

Clase de almacenamiento

11 - Combustible Solids

wgk

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

C Pellegrini et al.
NPJ Parkinson's disease, 8(1), 9-9 (2022-01-14)
Bowel inflammation, impaired intestinal epithelial barrier (IEB), and gut dysbiosis could represent early events in Parkinson's disease (PD). This study examined, in a descriptive manner, the correlation among enteric α-synuclein, bowel inflammation, impairments of IEB and alterations of enteric bacteria